Young Boys' Jordan Siebatcheu, left, scores his side's opening goal against Leverkusen's goalkeeper Niklas Lomb during the Europa League round of 32, 2nd leg soccer match between Bayer 04 ...

Bausch + Lomb is down 16.7% since the beginning of the year, and at $15 per share, it is trading 28.3% below its 52-week high of $20.93 from October 2024. Investors who bought $1,000 worth of ...

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Anyone seeking to report adverse effects should contact Bausch + Lomb at 800-338-2020, option 1, or submit a report to the FDA’s MedWatch program (800-332-1088 to request a form).

Bausch + Lomb beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $1.28 billion, up 9.1% year on year. It was a mixed quarter for the company, with a decent beat of ...

Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.

Bausch + Lomb is down 34.4% since the beginning of the year, and at $11.81 per share, it is trading 43.6% below its 52-week high of $20.93 from October 2024. Investors who bought $1,000 worth of ...

Bausch + Lomb also delivered full-year 2024 guidance that was better than expected. CEO Brent Saunders said the 2023 results, especially in the fourth quarter, "set the tone" for this year.

Bausch + Lomb Corp. announced June 30 that it will acquire XIIDRA, a treatment for dry eye disease, from Novartis for up to $2.5 billion.

Meanwhile, Bausch + Lomb is estimated to provide $4.7 billion in revenue and $860 million in EBITDA (earnings before interest, taxes, depreciation, and amortization) this year.

Bausch + Lomb said on Friday it would acquire several Novartis eye-care products for $1.75 billion as their market grows, sending the company's shares up over 8% in early trading.